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Abstract: Advances in stem cell research have provided important understanding of the 
cell biology and offered great promise for developing new strategies for tissue 
regeneration. The beneficial effects of stem cell therapy depend also by the development of 
new approachs for the track of stem cells in living subjects over time after transplantation. 
Recent developments in the use of nanotechnologies have contributed to advance of the 
high-resolution in vivo imaging methods, including positron emission tomography (PET), 
single-photon emission tomography (SPECT), magnetic resonance (MR) imaging, and X-
Ray computed microtomography (microCT). This review examines the use of 
nanotechnologies for stem cell tracking. 
Keywords:  stem cells; nanotechnologies; SPIO nanoparticles; X-ray microCT; in vivo 
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1. Introduction 
Cells have several advantages as a therapeutic or delivery system: they are able to carry out 
complex functions and they are responsive to changes in the surrounding tissue of host organism [1–5]. 
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The ability to non invasively monitor cell trafficking in vivo in a longitudinal fashion is a pressing 
need for emerging cellular therapeutic strategies. Monitoring of therapeutic cells is often conducted by 
histological analyses, which require sacrifice of the animal or tissue biopsies. Recently, non invasive 
imaging based monitoring methods (Figure 1) have been developed to track stem cell transplantation 
by labeling injected cells using nanotechnologies [6–15].  
Figure 1. Recent advances in nanotechnology for stem cell tracking. Anatomical and in 
vivo molecular imaging used to assist researchers in locating labeled stem cell. Methods for 
tracking stem cells in murine animal model such as MRI [56], MicroCT [17], Luciferase 
[57], Quantum Dot and Radionuclide [58] are shown in the upper panel. MRI and 
Radionuclide methods are also used in human studies. Improvement and combination of 
these methods will allow the quantification of migrating stem cells after their systemic use 
in clinical trials. In particular the future use of Micro-CT in vivo in humans should 
complete the need for new tracking methods (white arrow). Website sources for 
scintigraphy and FDG-PET: www.ifc.cnr.it; www.pmed.com. 
 
 
The goal is to track the distribution and migration of stem cells once introduced in the model 
organism. Examples include i) magnetic nanoparticles for stem cell labeling and successive 
visualization by in vivo MRI (Magnetic Resonance Imaging); ii) quantum dots or radionuclides for in Int. J. Mol. Sci. 2010, 11                 
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vivo visualization of stem cells by PET or SPECT. Moreover, the microCT offers high spatial 
resolution of the distribution of nanoparticles labeled stem cells and provides rapid reconstruction of 
3D images and quantitative volumetric analysis. In fact, the fate of injected stem cells in damaged 
tissues could be monitored by the X-ray micro CT after their labeling with SPIO (SuperParamagnetic 
Iron Oxide) nanoparticles. The aim of this review is to present some of recent progress obtained by 
using innovative and non-invasive imaging techniques and nanodiffraction involving nanotechnologies 
in research areas related to stem cells. In particular, we will focus on the fate of transplanted stem cell 
labeled with SPIO nanoparticles, as a treatment of muscular dystrophy of Duchenne in small animal 
models muscle, and tracked in vivo using X-Ray microCT. We recently identified a subpopulation of 
human circulating stem cells which participate actively to muscular regeneration when transplanted in 
dystrophic animal model migrating through the vasculature [16]. These cells can be labeled with 
nanoparticles and tracked by microCT [17]. MicroCT imaging is applicable to monitor the stem cell 
homing, after cell labeling with iron oxide nanoparticles. This technique also offers the possibility of 
obtaining a quantification of the number of cells that are able to migrate from the blood stream inside 
the muscle tissue, and a 3D visualization of their distribution and to detect small animal models in vivo 
at several times after the injection. 
2. Nanoparticles for in vivo MRI Visualization of Transplanted Stem Cells 
MRI has found extensive applications in stem cell imaging both in research and clinical settings 
[18–20]. MRI tracking of stem cells has largely relied upon ex vivo pre-labeling of stem cells with 
magnetic nanoparticles which can be internalized by the cells to generate strong MRI contrast [21]. 
MRI analysis presents a high spatial resolution and the advantage of visualizing transplanted cells 
within their anatomical surroundings, which is crucial for the description of migration processes. 
However, the level of sensitivity achieved by this technique is influenced by dilution of contrast 
agents, due to cell division, or the disposition of some of them to be transferred to non stem cells; in 
these cases the detected signal decreases and it’s not possible to correlate it to the injected cell number.  
The recent ability to directly label stem cells with magnetic resonance (MR) contrast agents provides a 
simple, straight-forward manner to monitor accurately cell delivery and track stem cells non-invasively 
in a serial manner. A variety of nanoparticles can be constructed to obtain MRI contrast [12,22] and 
peptide-conjugation approaches can be realized to label cells with multiple-detecting nanoparticles 
(magnetic, fluorescent, isotope) [23,24]; those currently in use typically range from 5 to 350 nm in 
diameter. These include superparamagnetic iron oxides (SPIO; 50–500 nm) and ultrasmall 
superparamagnetic iron oxides (USPIOs; 5–50 nm), which generally are coated with dextran or other 
polymers to maintain solubility and reduce particle agglomeration. SPIO nanoparticles represents the 
most widely used contrast agents for the detection of implanted cells in vivo because their contrast 
effect [25,26]. SPIO-labeled stem cells/progenitor cells might contribute to our understanding of cell 
migration processes in the context of numerous diseases, such as neurologic [27] and muscular 
diseases [28], myocardial infarction [29–31], and cancer [32]. For example, magnetically labeled 
mouse embryonic stem cells (mESCs), injected into the nonischemic side of the brain of a rat with 
partial brain ischemia, can be tracked during their migration along the corpus callosum, populating the 
border zone of the ischemic area of the contralateral hemisphere [26]. Moreover, SPIO- labeled human Int. J. Mol. Sci. 2010, 11                 
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neural stem cells can be visualized in mature rodent brain after their transplantationn [27]. In this case, 
the MRI demonstrated the migration capacity of labeled stem cells into the cortical region of the brain 
[27]. In addition to the information obtained from cell migration studies, SPIO technology might yield 
important information about the differentiation process of stem cells/progenitor cells. SPIO-labeled 
CD34+ progenitor cells injected into rodents can be isolated by magnetic separation after in vivo 
migration to study the differentiation of these cells exposed to a biological environment [33]. A 
clinical study using stem cells labeled with SPIO in patients with neurological disease has recently 
been reported [34]. This approach can be adapted to evaluate the therapeutic effects of stem cells in the 
context of other diseases, including myocardial infarction. In the literature is also reported the use of 
MRI to monitor the migration of magnetically labeled cells in early phase clinical trials [35]. 
Autologous dendritic cells were labeled with a clinical superparamagnetic iron oxide formulation or 
Indium Oxine™ (
111In oxyquinoline) and were co-injected intranodally in melanoma patient under 
ultrasound guidance. In contrast to scintigraphy imaging, by using MRI it was possible to serially 
monitor the migration of these through adjacent lymph nodes. It is important to note that the use of 
MRI contrast agents for magnet labeling of cells is considered an off-label use of the agent and at this 
time few superparamagnetic or paramagnetic agents have been approved by regulatory agencies for 
use to label cells. 
3. Radioisotope Labeling for PET and SPECT in vivo Imaging 
The PET and SPECT radionuclide imagine techniques allow the imaging of radiolabeled markers 
and their interaction with biochemical processes in living animals. Due to their nanomolar (<10
−9 M) 
sensitivity, PET and SPECT are able to measure biological process at very low concentrations. The 
mass of radiotracer injected is extremely small and does not impact the biological system under study. 
Technological developments of both PET and SPECT have led to the implementation of specialized 
systems for small animals imaging, with a better spatial resolution (<2 mm) and consequent 
advancement in the field of cell tracking in animals model in vivo.  
In general a radioisotope with a relatively long decay half life is use to enable the tracking of cells 
over period of several hours, or even days (
111In T ½= 2.8days). Numerous cell tracking experiments 
have been performed using cells labeled with a radioactive markers. 
111In-labeled cells have been 
widely used in humans in localizing areas of inflammation by imaging the leukocyte distribution [36]. 
Furthermore, 
111In-labeled cells have been applied in various experimental settings in animals to 
determine migration of dendritic cells [37], biodistribution of transplanted hepatocytes [38] and even 
homing of injected mesenchymal stem cells (MSCs) in animal models [39].   
Micro-single-photon-emission-computed-tomography (microSPECT/CT) small animal imaging 
system and an FDA-approved radiotracer (
111In oxyquinoline), has been use to demonstrate that 
monocyte recruitment to atherosclerotic lesions. With a noninvasive, dynamic, and three-dimensional 
fashion in live animals it is possible to track the monocytes recruitment to the atherosclerotic lesions in 
apolipoprotein E-deficient (ApoE−/−) mice. The long half-life of 
111In (2.8 days) enabled the detection 
of monocytes for up to seven days after adoptive transfer, and the high-resolution anatomical data 
derived from CT allowed localization of hotspots of monocyte infiltration in a sub-millimeter range 
[40]. Non invasive radionuclide imaging is also well suited to dynamically track the biodistribution Int. J. Mol. Sci. 2010, 11                 
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and trafficking of mesenchymal stem cells to both target and non target organs. MSCs isolated from 
bone marrow have the ability to differentiate into multiple cell lineages including osteocytes, 
chondrocytes, and cardiac myocytes. The recent ability to label MSCs with radiotracers provides a 
method to serially assess the biodistribution of these stem cells after intravenous administration with 
the use of radio-nuclide imaging as well as to determine the homing potential of MSCs to sites of 
injury [30]. The use of the high sensitivity of a combined single-photon emission CT (SPECT)/CT 
scanner, the in vivo trafficking of allogeneic mesenchymal stem cells (MSCs) labeled with a 
radiotracer and MR contrast agent to acute myocardial infarction was dynamically determined and 
redistribution of the labeled MSCs after intravenous injection from initial localization in the lungs to 
nontarget organs such as the liver, kidney, and spleen was observed within 24 to 48 hours after 
injection. Focal and diffuse uptake of MSCs in the infarcted myocardium was already visible in 
SPECT/CT images in the first 24 hours after injection and persisted until seven days after injection and 
was validated by tissue counts of radioactivity. Nevertheless, SPECT- and PET-based tracking of stem 
cells include nonspecific uptake of the radiotracer by normal tissue, relatively low efficiency of 
collimated SPECT cameras, and photon attenuation by tissue. Therefore, as concerns 
111In 
oxyquinoline ine labeling of human stem cells, the effect of radiation dose on human cell lines need to 
be carefully observed. A critical factor is to determine whether the 
111In oxyquinoline labeling affects 
viability, functionality, migration and proliferative capacity in distinct cell populations as well as 
species. 
4. Quantum Dots for Labeling Of Stem Cells 
Recent advances in nanotechnology offer some prospects to combine the best of each imaging 
technique with respect to sensitivity and specificity. There is now an array of artificial particulate 
systems used as diagnostic agents capable of targeting different cells in vivo. Those include colloidal 
gold, superparamagnetic iron-oxide crystals, dendrimers, polymeric micelles and liposomes, 
nanotubes, nanowires, nanoshells, and quantum dots (QDs). Quantum dots consist of semiconductor 
nanocrystals 2–5 nm in diameter, which have highly favorable fluorescence properties (broad band 
absorption spectra, narrow band emission, and high resistance to photobleaching) compared to 
commonly used fluorophores [41]. Fluorescent QDs possess several unique optical properties best 
suited for in vivo imaging [42, 43]. Because of quantum confinement effects, the emission color of 
QDs can be precisely tuned by size from the ultraviolet to the near-infrared. QDs are extremely bright 
and photostable. Colhera toxin subunit B (CTB)-quantum dots conjugates were developed for labeling 
mammalian cells. Several stem cell types were labeled with CTB-QD conjugates and quantum dots 
were completely dispersed throughout the cytoplasm in each cell type, presumably in vesicles [44]. 
Stem cells labeled appear to maintain their differentiation potential as well as stem cell properties 
[44].CTB-QD labeled muscle derived stem cells maintain similar percentage of expression for surface 
markers indicative of stem cell phenotype, such as stem cell antigen 1 (sca-1) and CD34. They can 
also form myotubes under serum deprivation, hence maintaining their myogenic potential following 
labeling with CTB-QD conjugates. The CTB-QD conjugates are likely to be suitable for long term cell 
tracking [44]. Functionalized quantum dots offer several advantages for tracking the motion of 
individual molecules on the cell surface, including selective binding, precise optical identification of Int. J. Mol. Sci. 2010, 11                 
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cell surface molecules, and details examination of the molecular motion. They were conjugated with 
integrin antibodies to perform studies about changes in the integrin dynamics during osteogenic 
differentiation of human bone marrow derived progenitors cells (BMPCs) [45]. It was possible to 
obtain a single particle tracking, by which it was possible to monitor and determine quantum dots 
conjugated integrin molecules on the surface of BMPC and to elucidate the physical constraints on the 
protein mobility at the cell surface.  
QDs long-term fluorescence makes them an important new class of nanomaterials available for 
stem cell tracking advance. Although QDs can be optically imaged, in vivo tracking typically requires 
a whole animal imaging. None of whole animal imaging systems have been employed so far to track 
QDs labeled stem cells in vivo. Moreover, QDs size and surface coating might affect their cellular 
internalization, their intracellular concentration and, consequently, the cytotoxicity of QDs. 
5. Nanotechnologies and MicroCT as a New Method for in vivo Cell Tracking 
MicroCT is similar to conventional CT systems usually employed in medical diagnoses and 
industrial applied research, but unlike these systems, which typically have a maximum spatial 
resolution of about 0.5 mm, advanced microCT is capable of achieving a spatial resolution up to  
0.3 μm, about three orders of magnitude lower. Use of synchrotron X-rays has several advantages 
compared to laboratory or industrial X- ray sources, such as high spatial resolution and a wide range of 
greyscale values (corresponding to different X-ray absorption coefficients) within and among   
datasets [46].  
More recently Synchrotron Radiation (SR) microCT systems were made available also for imaging 
small animals in vivo, such as for the examination of living rats [47] or mice [48]. The great advantage 
of such systems is to enable longitudinal studies, thus reducing the effect of biological variability in 
the cohort. The first in vivo longitudinal study reported alterations of bone micro-architecture in the 
hind limb loaded female rats [49]. In vivo microCT was also used to monitor microarchitectural 
changes in ovariectomized rats at the tibial metaphyses [50, 51]. It is a non-invasive technique giving 
integral information about the content of magnetic material along the beam direction as well as a 
relative local snapshot of the magnetic nanoparticle distribution in relation to the number of slices [52]. 
MicroCT provides high spatial resolution images (from 10 µm to 1 µm) with high signal-to-noise ratio. 
In previous study [17] we showed that X-ray microCT analysis is able to detect stem cells, previously 
labeled with nanoparticles of iron oxide (Endorem
®), inside skeletal muscles of dystrophic mice after 
intra-arterial transplantation, providing biological insights into the early processes of muscle stem cell 
homing.  
We explored the use of X-ray microCT as an experimental technique with high spatial resolution of 
1.65 µm for detection of stem cells. This technique also offers the possibility of obtaining a 
quantification of the number of cells that are able to migrate from the blood stream inside the muscle 
tissue, and a 3D visualization of their distribution. We analyzed nine muscular biopsies transplanted 
with three different numbers of stem cells labeled with iron-oxide nanoparticles, at three different 
times after injection. The different timing investigated did not show differences in the location of stem 
cells, while the variation in stem cells number allowed us to optimize the experimental conditions and 
identify 50,000 as the minimum number of detectable cells in a murine muscle. We showed that X-ray Int. J. Mol. Sci. 2010, 11                 
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microCT offers the possibility to detect with high definition and resolution human cells after 
transplantation, and opens new possibilities for stem cell research. In the perspective of clinical 
translation of stem cell research, it would be advantageous to develop new techniques to detect donor 
cells after transplantation to track their fate in vivo.  
6. Conclusions 
For clinical efficacy, it is imperative to image stem cells and their final location in vivo. Detection 
by MRI of magnetic nanoparticle-labeled stem cells may serve as a suitable means to achieve this 
objective; however, this technique has some limitations, such as the gradual loss of MRI cell signal 
due to cell division. It is also difficult to correlate the magnetic resonance signals to the number of 
cells detected. QDs might be an alternative for the long-term labeling of stem cells. However, the 
current cost of QDs labeling and accessibility of whole animal imaging is a barrier to large-scale 
studies.  
Further, quantum dots are not completely innocuous but they can induce alterations in the 
differentiation profile of stem cells [53,54], and abnormalities during embryonic development [55]. 
The luciferase based bioluminescence imaging technique has been extensively applied for non invasive 
imaging and for studying in vivo cells trafficking. However, several problems arose concerning the 
numbers of cells needed to develop in vivo experiments and also the quality of the images visualized. 
With the current advances in stem cells research, microCT imaging, as a non invasive technique, could 
be applied for tracking the transplanted stem cells and may be an important tool for monitoring the 
efficacy of stem cells transplantation.  
Combining the nanoparticles cell labeling and the X-ray microCT, it is possible to provide detailed 
information on the stem cell migration in 3D, which is not attainable by traditional methods based on 
2D techniques such as histology, scanning electron and fluorescence microscopy imaging. The 
microCT imaging could be applied on investigations of the homing specificity of various stem cell 
subtypes or genetically engineered stem cells in different cell-based therapies. We are going to explore 
the use of X-ray microCT with high spatial resolution of 7.5 µm for detection of stem cells in vivo. In 
particular, we labeled human CD133+ cells with nanoparticles of iron oxide and we injected them 
intra-arterially into skeletal muscles of dystrophic mice. We already were able to successfully detect 
stem cells in living mice at different time points. We know that these stem cells can migrate and they 
have the maximum migration rate in two hours after intra-arterial engraftment into scid/mdx mice, 
reaching a “plateau” after that time. Further studies are in progress to quantify the number of the stem 
cells migrated and more analyses are necessary to improve this method for future applications in the 
human tissues. 
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